Psychedelics as Medicines: An Emerging New Paradigm

D. E. Nichols, Matthew W Johnson, C. D. Nichols

Research output: Contribution to journalArticle

Abstract

Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5-HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. We propose that psychedelics exert therapeutic effects for psychiatric disorders by acutely destabilizing local brain network hubs and global network connectivity via amplification of neuronal avalanches, providing the occasion for brain network “resetting” after the acute effects have resolved. Antiinflammatory effects may hold promise for efficacy in treatment of inflammation-related nonpsychiatric as well as potentially for psychiatric disorders. Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.

LanguageEnglish (US)
Pages209-219
Number of pages11
JournalClinical Pharmacology and Therapeutics
Volume101
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Hallucinogens
Psilocybin
Psychiatry
Anti-Inflammatory Agents
Serotonin 5-HT2 Receptor Agonists
Avalanches
Receptor, Serotonin, 5-HT2A
Lysergic Acid Diethylamide
Brain
Therapeutic Uses
Psychotherapy
Tobacco
Anxiety
Alcohols
Depression
Inflammation
Research

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Psychedelics as Medicines : An Emerging New Paradigm. / Nichols, D. E.; Johnson, Matthew W; Nichols, C. D.

In: Clinical Pharmacology and Therapeutics, Vol. 101, No. 2, 01.02.2017, p. 209-219.

Research output: Contribution to journalArticle

Nichols, D. E. ; Johnson, Matthew W ; Nichols, C. D. / Psychedelics as Medicines : An Emerging New Paradigm. In: Clinical Pharmacology and Therapeutics. 2017 ; Vol. 101, No. 2. pp. 209-219.
@article{c6d71100be834e55af288eac36fdcfa0,
title = "Psychedelics as Medicines: An Emerging New Paradigm",
abstract = "Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5-HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. We propose that psychedelics exert therapeutic effects for psychiatric disorders by acutely destabilizing local brain network hubs and global network connectivity via amplification of neuronal avalanches, providing the occasion for brain network “resetting” after the acute effects have resolved. Antiinflammatory effects may hold promise for efficacy in treatment of inflammation-related nonpsychiatric as well as potentially for psychiatric disorders. Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.",
author = "Nichols, {D. E.} and Johnson, {Matthew W} and Nichols, {C. D.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1002/cpt.557",
language = "English (US)",
volume = "101",
pages = "209--219",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Psychedelics as Medicines

T2 - Clinical Pharmacology and Therapeutics

AU - Nichols, D. E.

AU - Johnson, Matthew W

AU - Nichols, C. D.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5-HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. We propose that psychedelics exert therapeutic effects for psychiatric disorders by acutely destabilizing local brain network hubs and global network connectivity via amplification of neuronal avalanches, providing the occasion for brain network “resetting” after the acute effects have resolved. Antiinflammatory effects may hold promise for efficacy in treatment of inflammation-related nonpsychiatric as well as potentially for psychiatric disorders. Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.

AB - Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5-HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. We propose that psychedelics exert therapeutic effects for psychiatric disorders by acutely destabilizing local brain network hubs and global network connectivity via amplification of neuronal avalanches, providing the occasion for brain network “resetting” after the acute effects have resolved. Antiinflammatory effects may hold promise for efficacy in treatment of inflammation-related nonpsychiatric as well as potentially for psychiatric disorders. Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.

UR - http://www.scopus.com/inward/record.url?scp=85009288244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009288244&partnerID=8YFLogxK

U2 - 10.1002/cpt.557

DO - 10.1002/cpt.557

M3 - Article

VL - 101

SP - 209

EP - 219

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -